Description

This edition of the Genetic TOE focuses on immunotherapies. Collaborations between Bristol-Myers Squibb (BMS) and Five Prime Therapeutics for developing Immunotherapies, Celgene and Jounce Therapeutics for developing a monoclonal antibody for cancer, Merck KGaA and Pfizer for developing ligand 1 checkpoint inhibitors, and Merck & Co. and Ablynx for a Nanobody program have been profiled.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Immunotherapies, monoclonal antibody, ligand 1 checkpoint inhibitors, nanobodies